ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
化工社オープンプロジェクト:[email protected]AIアクセス:llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.7.8
  1. ホーム
  2. /化合物

3-ヒドロキシ-3-シクロブテン-1,2-ジオン

Moniliformin

HCID 40452
ノート反応

データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます

基本情報名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
31876-38-7
標準SMILES
O=c1cc(O)c1=O
InChIKey
KGPQKNJSZNXOPV-UHFFFAOYSA-N
分子式
C4H2O3
平均分子量
98.06 g/mol
単同位体質量
98.00039392

名称と識別子

優先名称
Moniliformin
IUPAC
3-hydroxycyclobut-3-ene-1,2-dione
現地名
3-ヒドロキシ-3-シクロブテン-1,2-ジオン
英語名
moniliformin
分子式
C4H2O3
分子量
98.06

名称と別名

Moniliformin31876-38-73-hydroxycyclobut-3-ene-1,2-dioneSemisquaric acid3-Cyclobutene-1,2-dione, 3-hydroxy-1-Hydroxycyclobut-1-ene-3,4-dioneHydroxycyclobutenedione3-Hydroxy-3-cyclobutene-1,2-dione3-Hydroxy-3-cyclobutenedioneG5JMQ8SDF81-Hydroxy-cyclobut-1-ene-3,4-dioneDTXSID10185731
名称をさらに表示
3-ヒドロキシ-3-シクロブテン-1,2-ジオンセミスクアル酸3-ヒドロキシシクロブタ-3-エン-1,2-ジオン
RefChem:159498DTXCID50108222636-113-2981-476-51-hydroxycyclobutene-3,4-dioneNSC2928961345994-72-039284-13-4

データベース識別子

CAS
31876-38-7、71376-34-6
PubChem CID
40452
DTXSID
DTXSID10185731
ChEMBL
CHEMBL1977616
ChEBI
CHEBI:222613
UNII
G5JMQ8SDF8
EC Number
636-113-2、981-476-5
Nikkaji
J20.107C

物性

構造計算による物性補完中

XLogP
-0.6
極性表面積
54.4 Ų
水素結合供与体数
1
水素結合受容体数
3
回転可能結合数
0
重原子数
7
形式電荷
0
複雑度
166

物理化学的性質

融点
163 °C · 163°C (rough estimate)
沸点
123.51 °C · 123.51°C (rough estimate)
比重(密度)
1.3154 · 1.3154 (rough estimate)
屈折率
1.454 · 1.4540 (estimate)
酸解離定数(Pka)
-0.21 · -0.21±0.25(Predicted)

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 6 件

Danger

H301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]

P264, P270, P301+P316, P321, P330, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 41 reports by companies from 2 notifications to the ECHA C&L Inventory.;Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website.

危険有害性情報

Regulatory InformationRegulation (EC) No 178/2002 (amended)
Hazard Classes and Categories · 2 件

Acute Tox. 3 (100%)

Acute Tox. 2 (100%);Skin Irrit. 2 (100%);Eye Irrit. 2A (100%);STOT SE 3 (100%)

毒性情報

TreatmentKashin-Beck disease cannot be cured but can be treated with physical therapy and corrective surgery. Natamycin ophthalmic suspension is the drug of choice for filamentous fungal infections such as mycotic keratitis. (L1964, L1828)
Health Effects · 1 件

Moniliformin is believed to be a cause of Kashin-Beck disease, which causes joint destruction and deformity. It may also have immunosuppressive properties and can cause fungal infections such as mycotic keratitis. (A3021, A3075, A3076, L1970)

Exposure RoutesOral, dermal, inhalation, and parenteral (contaminated drugs). (A3101)
Toxicity Summary

化学と産業

用途と製造

UsesMoniliformin is a mycotoxin produced by a number of fungi of the Fusarium species. It can by found in contaminated cereal crops. (L1969, A3075)

応用分野

使用Moniliformin is a toxic secondary metabolite ofFusarium spp..

上流・下流製品情報

上流原料

ジクロロケテン3-Cyclobutene-1,2-dione, 3-chloro-4-hydroxy-2-Cyclobuten-1-one, 2,3,4-tris(1,1-dimethylethoxy)-Cyclobutanone, 2,2,3,3-tetraethoxy-Cyclobutene, 1,4-dichloro-3,3,4-trifluoro-2,3-di-tert-butoxy-4-hydroxy-2-cyclobuten-1-oneTetramethoxyethyleneケテンエチルビニルエーテル

関連反応

1 件
反応記録を作成
HRID 372627 の反応式
HRID 372627反応物としてuspto-grants-1978_05

化合物ノート

読み込み中…

このページの内容基本情報名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
· 1 件

Moniliformin reversibly inhibits the enzymes pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase by competing for the binding site of pyruvate. This interferes with the tricarboxylic acid cycle by preventing the necessary incorporation of pyruvate and oxidation of the alpha-ketoglutarate intermediate. Moniliformin has also been shown to interfere with carbohydrate metabolism by inhibiting transketolase and aldose reductase. Moniliformin causes the necrosis of human chondrocytes in cartilage. It does so by increasing the expression of matrix catabolic enzymes, such as MMP-1 and MMP-13, and decreasing the syntheses of extracellular matrix components such as aggrecan and type II collage. This accelerates the catabolism of the extracellular matrix in articular cartilages, inducing a loss of cartilage function and eventually leading to cartilage degradation. Moniliformin is also known to cause DNA damage, inducing chromatid breaks, chromosome breaks, and chromatid exchanges. (A3075, A3076, A3077)

Signs and Symptoms · 1 件

The main symptoms of acute moniliformin toxication in animals are muscular weakness, respiratory stress, myocardial degeneration, as well as some histopathological changes in organs such as the kidneys, the lungs and the pancreas, followed by coma and death. Kashin-Beck disease is characterized by joint pain, with restriction of movement and joint enlargement. (A3077)

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).

法規制情報

Regulatory InformationRegulation (EC) No 178/2002 (amended)